Research programme: pharmacological chaperones - Cantabio Pharmaceuticals

Drug Profile

Research programme: pharmacological chaperones - Cantabio Pharmaceuticals

Alternative Names: CB 101; CB 102

Latest Information Update: 25 Jul 2016

Price : $50

At a glance

  • Originator Gardedam Therapeutics; Purdue University
  • Developer Cantabio Pharmaceuticals
  • Class Proteins
  • Mechanism of Action Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 11 Jul 2016 Cantabio Pharmaceuticals signs a cooperation agreement with Purdue Research Foundation for studies on pharmacological chaperones for Parkinson's disease and other neurodegenerative disorders
  • 16 Jun 2016 Cantabio and University of Antioquia agree to co-develop DJ-1 protein-targeting small molecule in USA for Parkinson's disease
  • 25 Jan 2016 Preclinical trials in Parkinson's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top